Short answer
UroGen Pharma Ltd. (URGN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $89M (up 223.9% year over year) with net income of −$1M.
Q3 2026 key financials · XBRL
- Revenue
- $89M
- +223.9% YoY · +22.8% QoQ
- Net income
- −$1M
- +95.6% YoY · +89.8% QoQ
- Operating margin
- 9.4%
- Gross margin
- 91.6%
- EPS (diluted)
- −$0.03
- +95.7% YoY · +89.3% QoQ
Source: XBRL data from the UroGen Pharma Ltd. (URGN) Q3 2026 10-Q on SEC EDGAR. USD.
UroGen Pharma Ltd. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $89.0M vs $27.5M, up $61.5M YoY, driven primarily by Zusduri sales
- Gross margin 91.6% vs 88.1% YoY, operating margin 9.4% vs negative 99.7%
- Zusduri strongest growth driver, $61.5M revenue increase; Jelmyto standalone revenue not disclosed
- Cash and marketable securities $90.5M; operating cash use $93.5M through nine months
- Pharmakon refinancing provided $67.5M financing cash; management expects funding beyond one year, but may need additional capital
Risk Factors
- New tariff exposure: 15% U.S. tariff on imported mitomycin for Zusduri, effective September 29, 2026
- New financing structure: $200.0 million Pharmakon tranche refinanced $125.0 million outstanding debt, with $50.0 million available through June 30, 2027
- Most material operational risk: TAPI currently sole supplier of commercial mitomycin under April 2026 agreement
- Regulatory risk: FDA staffing reductions and policy changes could delay UGN-103 review, targeting June 14, 2027 action date
- Near-term market risk: Zusduri commercialization depends on physician adoption as the first FDA-approved nonsurgical treatment for recurrent low-grade intermediate-risk NMIBC
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UroGen Pharma Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.